CK19 and KIT Immunostaining is a Useful Adjunct to Ki-67-Based Grading of Pancreatic NET: A Study on Matched Cytological and Histological Samples Abstract #518

Introduction: Pancreatic neuroendocrine tumors (NET) are rare neoplasms. Recent evidence suggests that Ki-67 staining predicts their behavior. Even more recently, a prognostic role has been proposed also for CK19 and KIT. This panel might guide patient management. CK19 and KIT have not yet been evaluated on NET on Fine needle aspiration samples (FNAs).
Aim(s): To assess the feasibility of CK19 and KIT immunostaining assessment on pancreatic FNAs.
Materials and methods: Nine patients underwent EUS-FNA examination before surgery for primary (n=7) and metastatic (n=2) pancreatic NET. On site evaluation by an experienced cytopathologist ensured proper tissue handling for the prepration of a representative cell block for immunostainings. These latter were compared to those performed on the matched resected samples.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Prof. Giancarlo Troncone
Keywords: FNA, pancreas, NET, Ki-67, Kit, CK19

To read results and conclusion, please login ...

Further abstracts you may be interested in

#827 Neuroendocrine Tumors of the Pancreas Grade 2 with Ki-67 Index More Than 5% and with Expression Cytokeratin 19 are the Risk Group of Rapid Progression
Introduction: Cytokeratin 19 (CK19) is the marker of pluripotent cells of the epithelium of the pancreatic ducts, which is not detected in differentiated endocrine cells. Our experience shows that many patients with neuroendocrine tumors of the pancreas (pNET) G2 have a rapid progression of the disease a few years after diagnosis, and metastases are found most commonly in the liver.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Pathology, grading, staging
Presenting Author: MD Larisa Gurevich
#593 The Combination of CK19 and KIT is a Potential Predictor for Clinical Behaviors and Postoperative Outcomes in Resectable Pancreatic Neuroendocrine Tumors
Introduction: We assumed that pNETs is a disease triggered by the re-activation of developmental signaling pathways, once again expressing KIT and CK19.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Xu Han
Authors: Han X, Zhao J, Ji Y, Xu X, ...
Keywords: pNET, CK19, KIT
#2279 Expression of FOXM1 in G3 Neuroendocrine Tumors (NET G3) and G3 Neuroendocrine Carcinomas (NEC G3) of the Pancreas and the Intestine
Introduction: G3 gastroenteropancreatic neuroendocrine tumors (G3 NET) and carcinomas (G3 NEC) differ considerably concerning their biological behavior and patients outcome. Whereas the WHO2017 classification for pancreatic NETs proposes a distinction of both groups using the Ki-67 proliferation marker (Klöppel et al. Reviews and Reports 2017), a useful marker for the subclassification of G3 intestinal NETs have not been recommended until now.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dr. Franziska Briest
#979 Characteristics and Treatments of Patients with G3 Gastroenteropancreatic Neuroendocrine Tumors (G3-NET) and Neuroendocrine Carcinoma (NEC): A European Multicenter Retrospective Study
Introduction: Data on G3-NET and NEC are limited. No standard therapy following platinum-etoposide failure is established and first-line therapy in G3-NET is not codified.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Maximilian Heetfeld
#2757 Effectiveness of Lanreotide 120 mg (LAN) in Patients with Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumours (panNET) in Routine Clinical Practice
Introduction: PanNETs are the second most common type of tumour of the pancreas. Most patients have metastatic disease at diagnosis with median survival ranges from 2 to 5 years. Somatostatin analogs (SSAs) control symptoms and reduce tumour growth in panNET. In the panNET subgroup of the CLARINET study, lanreotide autogel 120 mg reduced the relative risk of progression or death by more than 40% compared with placebo at week 96.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: doctor Guillermo de La Cruz